Cell therapy for myocardial infarction: Special delivery

Cell Therapy for Acute Myocardial Infarction

In 1960, McCulloch and Till 1 identified a bone marrow stem cell capable of reconstituting hematopoiesis in mice, later documenting the clonality of these cells.2 The concept of the adult stem cell thus was born. More than 3 decades later, Asahara et al3 extended this concept to include the formation of vascular elements from bone marrow–derived, circulating endothelial progenitors. Although co...

Stem cell therapy for myocardial infarction.

Cell therapy for acute myocardial infarction.

Evidence suggesting that bone marrow and circulating blood may harbor myocardial and vascular progenitor cells was the basis for pre-clinical studies of cell therapy for acute myocardial infarction (MI). Rapid initiation of clinical trials has since followed, with regional myocardial delivery of autologous cells being tested as adjunctive therapies for both acute and chronic left ventricular dy...

[Stem cell therapy in acute myocardial infarction].

Remodeling of the left ventricle after myocardial infarction represents a major cause of infarct-related heart failure and death. Experimental data suggest that bone marrow-derived cells may contribute to the healing of myocardial infarction. The selective intracoronary transplantation of autologous, mononuclear bone marrow cells is safe and seems to be effective under clinical conditions conce...

Cell-based therapy of myocardial infarction.

Cell-based therapy is a promising option for treatment of ischemic diseases. Several cell types have experimentally been shown to increase the functional recovery of the heart after ischemia by physically forming new blood vessels, differentiating to cardiac myocytes and--additionally or alternatively--by providing proangiogenic and antiapoptotic factors promoting tissue repair in a paracrine m...